CTKB - Cytek Biosciences, Inc.
4.32
-0.260 -6.019%
Share volume: 556,843
Last Updated: 03-27-2026
Measuring And Control Equipment/Lab Analytical Instruments:
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$4.58
-0.26
-0.06%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-08-2024 | 08-06-2024 | 11-06-2024 | 02-27-2025 | 05-08-2025 | 11-05-2025 | 02-26-2026 | |
| Assets | ||||||||
| Total Assets | 492.067 M | 483.725 M | 491.226 M | 499.500 M | 482.596 M | 494.919 M | 461.542 M | |
| Current Assets | 388.647 M | 384.084 M | 390.191 M | 396.446 M | 380.501 M | 388.489 M | 391.996 M | |
| Inventories | 54.742 M | 50.070 M | 46.800 M | 43.893 M | 45.347 M | 51.649 M | 48.428 M | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 101.298 M | 99.323 M | 115.505 M | 179.145 M | 170.314 M | 168.453 M | 170.676 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 168.788 M | 177.888 M | 162.272 M | 98.716 M | 95.299 M | 93.281 M | 90.853 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 18.247 M | 18.114 M | 18.508 M | 17.962 M | 17.834 M | 18.046 M | 18.009 M | |
| Other Assets | 85.173 M | 81.527 M | 82.527 M | 85.092 M | 84.261 M | 88.384 M | 51.537 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 492.067 M | 483.725 M | 491.226 M | 499.500 M | 482.596 M | 494.919 M | 461.542 M | |
| Total liabilities | 99.453 M | 94.602 M | 105.763 M | 103.763 M | 102.973 M | 116.348 M | 119.803 M | |
| Total current liabilities | 55.566 M | 52.379 M | 62.797 M | 67.663 M | 67.691 M | 75.207 M | 77.804 M | |
| Accounts Payable | 3.725 M | 3.191 M | 5.389 M | 5.529 M | 6.247 M | 7.632 M | 6.410 M | |
| Other liabilities | 12.001 M | 11.247 M | 11.113 M | 10.966 M | 10.746 M | 16.668 M | 16.874 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 12.001 M | 11.247 M | 11.113 M | 10.966 M | 10.746 M | 16.668 M | 16.874 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 392.614 M | 389.123 M | 385.463 M | 395.737 M | 379.623 M | 378.571 M | 341.739 M | |
| Common stock | 429.515 M | 435.099 M | 430.202 M | 430.920 M | 426.833 M | 435.412 M | 441.236 M | |
| Retained earnings | -35.347 M | -45.781 M | -44.840 M | -35.199 M | -46.601 M | -57.662 M | -101.738 M |